Group 1 - Company atai Life Sciences is a clinical-stage biopharmaceutical firm focused on developing effective mental health treatments to improve patient outcomes [1][3] - The company has a pipeline of psychedelic-based therapies, including BPL-003 for treatment-resistant depression (TRD), VLS-01 for TRD, and EMP-01 for social anxiety disorder, all currently in Phase 2 clinical development [3] - atai is also working on a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD, aiming to provide scalable interventional psychiatry therapies [3] Group 2 - atai Life Sciences will participate in several investor conferences in September, including the Cantor Global Healthcare Conference on September 5, H.C. Wainwright Annual Global Investment Conference on September 8, and TD Cowen Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17 [1][2] - The format for these conferences will be fireside chats, and webcasts will be available on the company's website [2]

COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time in Boston, Massachusetts. A live webcast of the presentation will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available ...

PureTech Health (PRTC) H1 2025 Earnings Call August 28, 2025 09:00 AM ET Company ParticipantsAllison Talbot - SVP - CommunicationsRobert Lyne - Interim CEOSven Dethlefs - CEO - Celea TherapeuticsLuba Greenwood - CEOHeidi Jacobson - Equity Research AssociateEric Elenko - Co-Founder & PresidentConference Call ParticipantsMiles Dixon - Research Analyst - Healthcare & Life SciencesOperatorHello, everyone, and thank you for joining the Puretec Health twenty twenty five Half Year Earnings Webcast. My name is Samm ...

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce it has successfully expanded clinical-scale natural killer (“NK”) cells from cord blood units that have been ...

Highlighting multibillion-dollar drug discoveries and advancing novel oncology and immunotherapy assets AGOURA HILLS, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“OTLC” or the “Company”), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today highlights the depth of its oncology and immunotherapy pipeline while recognizing the extraordinary intellectual property contributions of its Chairman and CEO, Dr. Vuo ...

DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York. Presentation Details Date/ time: Tuesday, September 9 at 3:30 PM  ...

Core Viewpoint - Atossa Therapeutics is actively engaging with investors and the biotech community to discuss its clinical advancements and future milestones, particularly focusing on its lead product candidate, (Z)-endoxifen, which aims to innovate breast cancer treatment and prevention [1][3]. Group 1: Company Overview - Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment and prevention through innovative science and patient-focused solutions [6]. - The company's lead product candidate, (Z)-endoxifen, is being developed as a therapy across the breast cancer spectrum, including both prevention and treatment settings [6]. Group 2: Upcoming Events - Dr. Steven Quay, Chairman and CEO of Atossa, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET [1][3]. - The live presentation will be webcast, with a replay available for approximately 90 days on the company's investor website [4]. Group 3: Clinical Progress - Dr. Quay will provide updates on the clinical progress of (Z)-endoxifen, highlighting its dual mechanisms of action as a Selective Estrogen Receptor Modulator (SERM) that may offer a differentiated solution for breast cancer prevention and treatment [3]. - Recent feedback from regulatory advisors has been encouraging, which could potentially accelerate the company's development path [3].

Core Insights - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [2] - The company will participate in investor meetings at upcoming conferences in September 2025 [1] Company Overview - CorMedix's lead product, DefenCath (taurolidine and heparin), was approved by the FDA on November 15, 2023 [2] - The commercial launch of DefenCath began in inpatient settings in April 2024 and in outpatient settings in July 2024 [2] - In 2025, CorMedix commenced clinical studies for Total Parenteral Nutrition and Pediatric patient populations, with plans to develop DefenCath as a catheter lock solution for other patient populations [2]

Core Viewpoint - Candel Therapeutics, Inc. is actively engaging with investors through participation in multiple upcoming conferences, highlighting its focus on developing innovative immunotherapies for cancer treatment [1][2]. Group 1: Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating off-the-shelf multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses [3]. - The company has developed two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [3]. Group 2: Product Development - Candel's lead product candidate, CAN-2409, has successfully completed phase 2a clinical trials for non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and is undergoing a pivotal phase 3 trial for localized prostate cancer [4]. - CAN-2409 has received several designations from the FDA, including Regenerative Medicine Advanced Therapy Designation for localized prostate cancer, and Fast Track Designation for both NSCLC and prostate cancer [4]. - The second lead product candidate, CAN-3110, is currently in a phase 1b clinical trial for recurrent high-grade glioma (rHGG) and has also received Fast Track and Orphan Drug Designations from the FDA [5]. Group 3: Upcoming Events - Candel Therapeutics will participate in the following investor conferences: - Citi's 2025 Biopharma Back to School Conference on September 3, 2025, at 9:00 AM ET [2]. - Cantor Global Healthcare Conference on September 4, 2025, at 8:00 AM ET [2]. - H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025, at 7:00 AM ET [2]. - Live webcasts of these presentations will be available and archived for up to 90 days [2].

BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a revised preliminary non-binding proposal letter (the "Revised Proposal Letter"), dated August 26, 2025, from a consortium ...